$ARDM SHOULD BE HEADING UP INTO 2 BIG Catalysts - HEADING UP TO $8
1- ADCOM DAY ON JAN 11 2018
2- PDUFA date - priority review January 26, 2018. Phase 3 data released December 1, 2016.
Drug: Linhaliq (Pulmaquin) for Non-cystic fibrosis bronchiectasis (non-CF BE).